Boutique RWE · HEOR · Clinical Trial Analytics
From Fragmented Data to Defensible Evidence.
Boutique advisory in real-world data, evidence, epidemiology and clinical trial analytics, synthesizing fragmented data into evidence that is rigorous, traceable, and ready for regulatory and payer scrutiny.
Boutique advisory in real-world data, evidence, epidemiology and clinical trial analytics, synthesizing fragmented data into evidence that is rigorous, traceable, and ready for regulatory and payer scrutiny.
Boutique RWE · HEOR · Clinical Trial Analytics
From Fragmented Data to Defensible Evidence.
Boutique advisory in real-world data, evidence, epidemiology and clinical trial analytics, synthesizing fragmented data into evidence that is rigorous, traceable, and ready for regulatory and payer scrutiny.
Boutique advisory in real-world data, evidence, epidemiology and clinical trial analytics, synthesizing fragmented data into evidence that is rigorous, traceable, and ready for regulatory and payer scrutiny.
Boutique RWE · HEOR · Clinical Trial Analytics
From Fragmented Data to Defensible Evidence.
Boutique advisory in real-world data, evidence, epidemiology and clinical trial analytics, synthesizing fragmented data into evidence that is rigorous, traceable, and ready for regulatory and payer scrutiny.
Boutique advisory in real-world data, evidence, epidemiology and clinical trial analytics, synthesizing fragmented data into evidence that is rigorous, traceable, and ready for regulatory and payer scrutiny.
Who we are
We bridge science and system.
Novida Analytics is a boutique advisory practice in real-world data, real-world evidence, epidemiology, and demography. We synthesize fragmented data into evidence that supports drug development decisions, drawing on publicly available and underutilized sources alongside proprietary databases and methodological frameworks to generate insights that are rigorous, traceable, and ready for regulatory and payer scrutiny.
We bridge the gap between the clinical and scientific experts who understand what evidence is needed, and the data science and technology teams building the systems to generate it.
Our focus is on assets from Phase 2 of drug development, where the cost of fragmented or poorly synthesized data is most consequential.
The Problem we Solve
3 design failures. All preventable.
Trials designed without disease epidemiology grounding.
Patient populations are misestimated. Sites are misidentified. These are design failures, not execution failures.
Evidence generated in silos.
RWE, regulatory, and market access evidence are planned independently. Critical gaps surface too late to fill. Study sequencing is reactive.
Scientific intent lost in technical translation.
Technical teams cannot define what to build. Scientific teams cannot specify it in buildable terms. The result is tools that miss the mark.
Who we Serve
You are the right client if...
Tier 2 Biopharma and Biotech
Phase 2 and Phase 3 assets. Lean internal teams. You need senior RWE or epidemiology expertise you do not have in-house.
Health Tech and MedTech
Building pharma-facing tools or intelligence systems. You need a domain expert to define what to build before your developers start.
Mid-size CROs
A specific engagement. Senior RWE or epidemiology expertise your team does not have for that project.
Medical Affairs and Evidence Teams
Building or improving evidence planning capabilities, with or without a technology layer.
Who we are
We bridge science and system.
Novida Analytics is a boutique advisory practice in real-world data, real-world evidence, epidemiology, and demography. We synthesize fragmented data into evidence that supports drug development decisions, drawing on publicly available and underutilized sources alongside proprietary databases and methodological frameworks to generate insights that are rigorous, traceable, and ready for regulatory and payer scrutiny.
We bridge the gap between the clinical and scientific experts who understand what evidence is needed, and the data science and technology teams building the systems to generate it.
Our focus is on assets from Phase 2 of drug development, where the cost of fragmented or poorly synthesized data is most consequential.
The Problem we Solve
3 design failures. All preventable.
Trials designed without disease epidemiology grounding.
Patient populations are misestimated. Sites are misidentified. These are design failures, not execution failures.
Evidence generated in silos.
RWE, regulatory, and market access evidence are planned independently. Critical gaps surface too late to fill. Study sequencing is reactive.
Scientific intent lost in technical translation.
Technical teams cannot define what to build. Scientific teams cannot specify it in buildable terms. The result is tools that miss the mark.
Who we Serve
You are the right client if...
Tier 2 Biopharma and Biotech
Phase 2 and Phase 3 assets. Lean internal teams. You need senior RWE or epidemiology expertise you do not have in-house.
Health Tech and MedTech
Building pharma-facing tools or intelligence systems. You need a domain expert to define what to build before your developers start.
Mid-size CROs
A specific engagement. Senior RWE or epidemiology expertise your team does not have for that project.
Medical Affairs and Evidence Teams
Building or improving evidence planning capabilities, with or without a technology layer.
Who we are
We bridge science and system.
Novida Analytics is a boutique advisory practice in real-world data, real-world evidence, epidemiology, and demography. We synthesize fragmented data into evidence that supports drug development decisions, drawing on publicly available and underutilized sources alongside proprietary databases and methodological frameworks to generate insights that are rigorous, traceable, and ready for regulatory and payer scrutiny.
We bridge the gap between the clinical and scientific experts who understand what evidence is needed, and the data science and technology teams building the systems to generate it.
Our focus is on assets from Phase 2 of drug development, where the cost of fragmented or poorly synthesized data is most consequential.
The Problem we Solve
3 design failures. All preventable.
Trials designed without disease epidemiology grounding.
Patient populations are misestimated. Sites are misidentified. These are design failures, not execution failures.
Transparent methodology
RWE, regulatory, and market access evidence are planned independently. Critical gaps surface too late to fill. Study sequencing is reactive.
Transparent methodology
Technical teams cannot define what to build. Scientific teams cannot specify it in buildable terms. The result is tools that miss the mark.
Who we Serve
You are the right client if...
Tier 2 Biopharma and Biotech
Phase 2 and Phase 3 assets. Lean internal teams. You need senior RWE or epidemiology expertise you do not have in-house.
Health Tech and MedTech
Building pharma-facing tools or intelligence systems. You need a domain expert to define what to build before your developers start.
Transparent methodology
A specific engagement. Senior RWE or epidemiology expertise your team does not have for that project.
Transparent methodology
Building or improving evidence planning capabilities, with or without a technology layer.
Why Novida
Boutique by design. Not by limitation.
Every client works directly with a senior expert who has solved these problems at scale. Every deliverable is built to be defended, not just delivered.
VS. GENERALIST CONSULTING FIRMS
Deep specialization in RWD, RWE, epidemiology, and demography. Proprietary databases and methodological frameworks. Outputs structured for regulatory and HTA defensibility.
VS. LARGE CROS
The expert who scopes the engagement is the expert who delivers it. No hand-off. No procurement overhead. Integrates with your team rather than displacing it.
VS. DATA PLATFORM VENDORS
Vendor agnostic. Data interpreted and connected, not just retrieved. Measured by quality and defensibility of the output, not platform adoption. No lock-in.
VS. HEALTH TECH VENDORS
Defines what good looks like before any tool is selected or built. Validates existing tools against the regulatory standards that matter. Acts as your scientific advisor, not as a vendor.
Why Novida
Boutique by design. Not by limitation.
Every client works directly with a senior expert who has solved these problems at scale. Every deliverable is built to be defended, not just delivered.
VS. GENERALIST CONSULTING FIRMS
Deep specialization in RWD, RWE, epidemiology, and demography. Proprietary databases and methodological frameworks. Outputs structured for regulatory and HTA defensibility.
VS. LARGE CROS
The expert who scopes the engagement is the expert who delivers it. No hand-off. No procurement overhead. Integrates with your team rather than displacing it.
VS. DATA PLATFORM VENDORS
Vendor agnostic. Data interpreted and connected, not just retrieved. Measured by quality and defensibility of the output, not platform adoption. No lock-in.
VS. HEALTH TECH VENDORS
Defines what good looks like before any tool is selected or built. Validates existing tools against the regulatory standards that matter. Acts as your scientific advisor, not as a vendor.
Why Novida
Boutique by design. Not by limitation.
Every client works directly with a senior expert who has solved these problems at scale. Every deliverable is built to be defended, not just delivered.
Stay curiousFull Team Delivery
Deep specialization in RWD, RWE, epidemiology, and demography. Proprietary databases and methodological frameworks. Outputs structured for regulatory and HTA defensibility.
Own the outcomeExpert Integration
The expert who scopes the engagement is the expert who delivers it. No hand-off. No procurement overhead. Integrates with your team rather than displacing it.
Own the outcomeExpert Integration
Vendor agnostic. Data interpreted and connected, not just retrieved. Measured by quality and defensibility of the output, not platform adoption. No lock-in.
Own the outcomeExpert Integration
Defines what good looks like before any tool is selected or built. Validates existing tools against the regulatory standards that matter. Acts as your scientific advisor, not as a vendor.
FAQ
What clients ask us most
We’re here for follow-up questions too find us on the contact page
What types of organisations do you work with?
Mid-size biopharma and biotech with active US clinical programmes; CROs needing specialised epidemiology or HEOR capabilities; medical affairs teams building RWE packages; biotech startups with complex eligibility criteria or rare disease populations; analytics and evidence teams embedding RWE into clinical development planning.
Do you work with clients who have internal RWE/HEOR teams?
Yes - Novida provides senior methodological leadership while your team executes. We build alongside your specialists, not around them.
How long does a typical engagement last?
Epidemiology landscape review: 3–6 weeks. Enrollment feasibility study: 6–10 weeks. RWD landscape assessment: 3–5 weeks. Comparative effectiveness study: 12–20 weeks. Economic model development: 8–14 weeks. HTA dossier support: 10–18 weeks. Strategic advisory: 4–8 weeks or ongoing retainer.
What is your pricing model?
All engagements are scoped before pricing. We do not publish rate cards. Pricing is determined by data complexity, therapeutic area, regulatory context, timeline, and team composition. Indicative investment ranges are provided at the scoping proposal stage, within 5 business days of the discovery call.
Do you offer ongoing support after delivery?
Yes. Every project engagement includes a review cycle and full documentation handoff. Optional follow-on advisory is available. Our advisory retainer provides ongoing access across multiple questions during active development. The embedded analyst model provides the deepest ongoing integration.
How do I get started?
Email info@novidaanalytics.com with a brief description of your project, indication, and timeline. We respond within 2 business days. Discovery call (30–45 minutes, no obligation) → scoping proposal within 5 business days → engagement agreement → kickoff.
FAQ
What clients ask us most
We’re here for follow-up questions too find us on the contact page
What types of organisations do you work with?
Mid-size biopharma and biotech with active US clinical programmes; CROs needing specialised epidemiology or HEOR capabilities; medical affairs teams building RWE packages; biotech startups with complex eligibility criteria or rare disease populations; analytics and evidence teams embedding RWE into clinical development planning.
Do you work with clients who have internal RWE/HEOR teams?
Yes - Novida provides senior methodological leadership while your team executes. We build alongside your specialists, not around them.
How long does a typical engagement last?
Epidemiology landscape review: 3–6 weeks. Enrollment feasibility study: 6–10 weeks. RWD landscape assessment: 3–5 weeks. Comparative effectiveness study: 12–20 weeks. Economic model development: 8–14 weeks. HTA dossier support: 10–18 weeks. Strategic advisory: 4–8 weeks or ongoing retainer.
What is your pricing model?
All engagements are scoped before pricing. We do not publish rate cards. Pricing is determined by data complexity, therapeutic area, regulatory context, timeline, and team composition. Indicative investment ranges are provided at the scoping proposal stage, within 5 business days of the discovery call.
Do you offer ongoing support after delivery?
Yes. Every project engagement includes a review cycle and full documentation handoff. Optional follow-on advisory is available. Our advisory retainer provides ongoing access across multiple questions during active development. The embedded analyst model provides the deepest ongoing integration.
How do I get started?
Email info@novidaanalytics.com with a brief description of your project, indication, and timeline. We respond within 2 business days. Discovery call (30–45 minutes, no obligation) → scoping proposal within 5 business days → engagement agreement → kickoff.
FAQ
What clients ask us most
We’re here for follow-up questions too find us on the contact page
What types of organisations do you work with?
Mid-size biopharma and biotech with active US clinical programmes; CROs needing specialised epidemiology or HEOR capabilities; medical affairs teams building RWE packages; biotech startups with complex eligibility criteria or rare disease populations; analytics and evidence teams embedding RWE into clinical development planning.
Do you work with clients who have internal RWE/HEOR teams?
Yes - Novida provides senior methodological leadership while your team executes. We build alongside your specialists, not around them.
How long does a typical engagement last?
Epidemiology landscape review: 3–6 weeks. Enrollment feasibility study: 6–10 weeks. RWD landscape assessment: 3–5 weeks. Comparative effectiveness study: 12–20 weeks. Economic model development: 8–14 weeks. HTA dossier support: 10–18 weeks. Strategic advisory: 4–8 weeks or ongoing retainer.
What is your pricing model?
All engagements are scoped before pricing. We do not publish rate cards. Pricing is determined by data complexity, therapeutic area, regulatory context, timeline, and team composition. Indicative investment ranges are provided at the scoping proposal stage, within 5 business days of the discovery call.
Do you offer ongoing support after delivery?
Yes. Every project engagement includes a review cycle and full documentation handoff. Optional follow-on advisory is available. Our advisory retainer provides ongoing access across multiple questions during active development. The embedded analyst model provides the deepest ongoing integration.
How do I get started?
Email info@novidaanalytics.com with a brief description of your project, indication, and timeline. We respond within 2 business days. Discovery call (30–45 minutes, no obligation) → scoping proposal within 5 business days → engagement agreement → kickoff.
Ready to grow together?
Ready to grow together?